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Clinical trials have provided a substantial body of data con- 
cerning risk factor modification i  patients with atherosclerotic 
disease and have allowed identification of patient subgroups 
most likely to benefit from specific therapy. In this Task Force 
4, we analyze this evidence, using the classification system from 
Task Force 3. 
Proposed risk factor categories: 
I. Factors for which interventions have beenproved to lower 
coronary artery disease risk. 
II. Factors for which interventions are lik@ to lower coro- 
nary artery disease risk. 
III. Factors that, if modified, might lower coronary artery 
disease risk. 
IV. Factors that cannot be modified or for which modification 
would be unlik@ to lower coronary disease risk. 
I. Factors for Which Interventions Have 
Been Proved to Lower Coronary 
Artery Disease Risk 
In the past 40 years, the age-adjusted mortality rate from 
coronary heart disease and other vascular conditions in the 
United States has declined by 40% (1). It is estimated that 
more than half of this mortality decline is related to decreases 
in serum cholesterol and cigarette smoking (2). 
There is a large body of epidemiologic data that link serum 
cholesterol to coronary morbidity and mortality. Among the 
most dramatic data is the roughly linear relationship between 
the level of serum cholesterol and coronary disease mortality, 
most recently among 19 countries (3). From these studies 
we estimate that the variation in serum cholesterol level 
accounts for 45% of the population differences in coronary 
artery disease mortality. There are many studies, including the 
Framingham Heart Study (4) and the Multiple Risk Factor 
Intervention Trial (MRFIT) (5), that confirm the positive, 
continuous, graded and progressive relationship between cor- 
onary artery disease and the level of serum cholesterol. These 
data have provided the basis for the clinical trials directed at 
lowering serum lipids and lipoproteins. 
Diet 
Essentially all pharmacologic lipid modification trials have 
utilized dietary counseling, and dietary modification may fa- 
vorably influence other risk factors in addition to its effect on 
lipids. Dietary therapy has been assessed as a primary inter- 
vention in seven randomized clinical trials performed in pa- 
tients with coronary artery disease. Three early trials (6-8) 
used modest fat-restricted diets that resulted in minimal serum 
cholesterol reductions and failed to demonstrate beneficial 
effects on cardiac events. Of the four later trials (9-12), three 
demonstrated statistically significant reductions, ranging from 
32% to 66% in cardiac mortality (9,11,12). These low fat diets 
were high in fiber and antioxidant-rich foods (12), monosatu- 
rated fat (11) or fish (9). Notably, the impact of these diets on 
serum lipids demonstrated relatively mild effects on reducing 
serum cholesterol, ranging from 0% to 15%, suggesting that 
their beneficial impact may operate through alternative mech- 
anisms. 
Low fat diets also have been effective in reducing the 
prevalence of angiographic progression of coronary disease, 
when combined with exercise (13) and stress management 
(14). Moreover, angiographic trials have shown that high levels 
of dietary fat predict progression of disease independent of 
serum lipid levels and type of lipid-lowering drug therapy, 
whereas regression is related to lipid lowering (15). 
Populations consuming diets rich in fish have a low rate of 
coronary artery disease (16). However, dietary intake of fish oil 
has not been consistently correlated with coronary artery 
disease incidence, and increased consumption of fish was not 
associated with a reduced risk of coronary artery disease in the 
Health Professionals Follow-up Study (17). Dietary fish oil 
supplemention has been associated with inhibition of experi- 
mental atherosclerosis induced by dietary hyperlipidemia and 
balloon angioplasty. Meta-analyses of clinical trials have sug- 
gested that restenosis after coronary angioplasty may be re- 
duced by supplemental fish oils in a dose-dependent manner 
(18,19). However, the results are inconclusive, and additional 
well designed trials with larger numbers, objective quantitative 
measures and more complete follow-up are needed. 
Total Cholesterol and Low Density 
Lipoprotein Cholesterol 
The most conclusive vidence that blood lipids are causally 
related to the development of coronary artery disease is 
derived from randomized, controlled clinical trials. Both pri- 
992 FORRESTER ET AL. JACC Vol. 27, No. 5 
TASK FORCE 4 April 1996:964-1047 
Table 1. Coronary Events in Early Cholesterol-Lowering Trials 
Definitive Fatal and 
Duration No. of % Change in Nonfatal CHD 
Trial (ref. no.) (yr) Intervention Pts Cholesterol [no. (%) of pts] 
Los Angeles VA (28) 8 Control 422 71 (16.8) 
Diet 444 - 14 54 (12.3) 
MRC low fat (25) 3 Control 129 31 (24.0) 
Det 123 -9  30 (24.4) 
MRC soya oil (26) 4 Control 194 51 (26.3) 
Diet 199 - 13 45 (22.6) 
Oslo Diet Heart (10) 4 Control 206 81 (39.3) 
Diet/smoking 206 - 15 61 (29.6)* 
LRC-CPPT (20) 5 Diet 1,900 187 (9.8) 
Diet/cholestyramine 1,906 -9 155 (8.1)* 
Helsinki Heart (29) 5 Diet 2,030 84 (4.1) 
Diet/gemfibrozil 2,051 - 10 56 (2.7) * 
WHO clofibrate (21) 5 Control 5,296 208 (3.9) 
Clofibrate 5,331 -8  167 (3.1)* 
Coronary Drug Project (22) 6 Control 2,789 839 (30.1) 
Clofibrate 1,103 -6  309 (28.0) 
Newcastle (24) 5 Control 253 81 (32.0) 
Clofibrate 244 - 10 52 (21.3)* 
Edinberg (23) 6 Control 367 72 (19.6) 
Clofibrate 350 - 14 54 (15.4) 
Stockholm (27) 5 Control 276 100 (36.2) 
Clofibrate/niacin 279 - 13 72 (25.8)* 
Niacin 1,119 - 10 287 (25.6) *
*p = <0.05 treatment group versus control group. CHD = coronary heart disease; LRC-CPPT = Lipid Research 
Clinics-Coronary Primary Prevention Trial; MRC = Medical Research Council; Pts = patients; ref. = reference; VA = 
Veterans Administration; WHO = World Health Organization. 
mary and secondary prevention trial data indicate that choles- 
terol lowering, specifically low density lipoprotein (LDL) cho- 
lesterol in men, is associated with a reduced risk of coronary 
artery disease. 
The majority of the evidence before the mid-1980s came 
from clinical trials of cholesterol lowering on the incidence of 
clinical events (Table 1) (10,20-29). The therapeutic nterven- 
tion most commonly consisted of diet and monodrug therapy, 
involving the bile-acid sequestrants (cholestyramine), fibrino- 
lytic acids (gemfibrozil and clofibrate) or niacin. Most of these 
early trials measured only cholesterol and triglycerides. Rou- 
tine measurement of lipoproteins did not begin until the 
mid-1970s, with the Lipid Research Clinic-Coronary Primary 
Prevention Trial (LRC-CPPT) and Helsinki studies. The re- 
duction in total cholesterol in these arly trials ranged from 6% 
to 15%. A consistent trend toward a reduction in fatal and 
nonfatal coronary artery disease was observed in all studies. In 
seven of the individual trials, the reduction in coronary artery 
disease events was statistically significant. The pooled data 
suggested that a 1% reduction in total cholesterol isassociated 
with a 2% reduction in clinical events. In studies conducted for 
more than 5 years, the reduction in clinical events increased to 
3% for each 1% reduction in total cholesterol. 
In the mid-1980s, the focus switched to angiographic trials 
(13,30-33) (Table 2) that could be performed with a much 
smaller number of participants and provided a direct assess- 
ment of vascular pathologic anatomy. Earlier clinical observa- 
tions and small uncontrolled trials (34,35) had suggested that 
cholesterol lowering was associated with reduced rates of 
progression of atherosclerotic disease. The initial larger scale 
trials employed qualitative reading of matched pairs of anglo- 
grams that were categorized as progression, regression or no 
change. In virtually all cases, the treatment groups demon- 
strated less progression, more stability of lesions and more 
regression than the control groups. 
These studies were followed by the major quantitative 
angiographic trials (36-44) (Table 3). With the exception of 
the Harvard Atherosclerosis Reversibility Project (HARP) 
study (39), which included a small number of subjects with a 
mean baseline LDL cholesterol f 138 mg/dl (lower than most 
other studies), all of the treated groups showed a decrease in 
the percent mean stenosis and minimal umen diameter com- 
pared with control subjects. There was, however, considerable 
variability in the magnitude of change reported in different 
trials. 
The clinical outcomes in these trials were characterized by 
a large percentage decrease in clinical events, although the 
absolute values were small and the reporting was not complete. 
There were 91 deaths (4.8%) reported in the control groups 
versus 75 (3.8%) in the treated groups. Similar differences in 
magnitude were observed in coronary deaths (3.4% vs. 2.5%) 
and the number of fatal and nonfatal myocardial infarctions 
(9.6% vs. 6.6%). Although the number of coronary artery 
bypass grafts and percutaneous transluminal coronary angio- 
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Table 2. Qualitative Angiographic Trials 
Events* 
% Change Compared 
With Control Group % of Pts Mortality 
Study Duration No. of All 
(ref. no.) (yr) Intervention Pts TC LDL HDL TG Prog No Chg Regr All Card MI 
NHLBI 5 Placebo 57 51 42 7 - -  - -  - -  
(31) Cholestyramine 59 -16 -21 +6 +6 41 52 7 - -  - -  - -  
CLAS-I 2 Placebo 94 61.0 36.6 2.4 1 1 4 
(30) Colestipol/niacin 94 -26 -43 +37 -22 38.8 45.0 16.2 0 0 1 
CLAS-II 4 Placebo 63 87 7 7 - -  1 6 
(33) Colestipol/niacin 75 -25 -40 +37 -18 48 34 18 - -  1 3 
Heidelberg 1 Usual care 57 2 1 3 
(13) Diet/exercise 56 -10 -11 +3 -24 3 3 3 
POSCH? 5 Usual care 41 -5  -7  - 1 -4  65.4 29.9 4.7 62 44 138 
(32) Ileal bypass 7 -28 -42 +5 +11 37.5 37.5 12.6 49 32 91 
*Absolute number of patients with an event. ?Events data are for 10-year follow-up+ Card = cardiac related; Chg = change; CLAS-I, CLAS-II = Cholesterol Lowering 
Atherosderosis Study; HDL = high density lipoprotein; LDL = low density cholesterol; M1 = myocardial infarction; NHLBI = National Heart, Lung, and Blood Institute; 
POSCH = Program on the Surgical Control of the Hyperlipidemias; Prog = progressive; Regr = regression; TC = total cholesterol; TG = triglycerides; other abbreviations 
as in Table 1. 
plastics were not reported in many studies, when reported, 
there were 179 interventions in the control group versus 113 in 
the treated group. The trials also showed that patients with 
angiographic progression were more likely to experience a 
clinical event. An unpublished preliminary recta-analysis (45) 
of 2,076 participants in 11 trials suggests that both LDL and 
Table 3. Quantitative Angiographic Trials 
% Change Events? 
Minimal Mortality 
Trial Duration No. of % Change Mean Lumen All CABG/ 
(ref. no.) (yr) Pts* Intervention TC LDL HDL TG Stenosis Diameter All Cardiac MI PTCA 
FATS (36) 2.5 146 (46) Placebo/colestipol -4  -7  +5 +15 +2.1 -0.50 0 0 0 10 
(38) Lovastatin/colestipol -23 -46 +15 -29 -0.9 -0.035 1 1 2 2 
(36) Niacin/colestipol -34 -32 +43 -9  -0.7 -0.012 0 0 0 2 
SCOR (37) 2.3 32(15) Placebo/colestipol -8.6 -10.6 +1 +4 +0.80 - -  - -  - -  1 - -  
40 (32) Colestipol/niacin 31 -38.1 +25.4 -21 -1.53 - -  - -  - -  0 - -  
Lovastatin 
Lifestyle (14) 1 20(19) Control -5  -6  -3  -8.5 +3.4 - -  0 - -  - -  - -  
28 (22) Diet/life-style -24 -37 -3  +22 -2.2 - -  1 - -  - -  - -  
STARS (40) 3.4 90 (24) Usual care -2  -3  -1 +1 +5.8 -0.232 3 3 2 4 
(26) Diet -14 -16 0 -20 -1.1 +0.030 1 1 1 1 
(24) Diet/cholestyramine -25 -36 -4  0 -1.9 +0.117 0 0 1 0 
MARS (38) 2.2 270(124) Placebo -1.8 0.9 +2.3 +3.5 +2.2 1 - -  - -  31:]: 
(123) Lovastatin - -  -38.0 +8.5 -21.6 +1.6 2 - -  - -  22:I: 
32.2 
HARP (39) 2.5 79 (39) Control 0 +3 0 -20 +2.3 0.15 mm - -  - -  0 3 
(40) Intensive drugs -28 39 +13 +1 +2.1 0.14mm - -  - -  2 2 
(one to four lipid drugs) - -  - -  
CCAIT (43) 2 166 (153) Placebo 1.4 -1.6 +3.0 +3.8 +2.9 -0.09 2 1 6 - -  
165 (146) Lovastatin -21 -29 +7.3 -8.1 +1.7 -0.05 2 2 5 - -  
SCRIP (42) 4 155(127) Usual care -2  -4  +5.5 +0.6 0.7§ -0.045§ 3 3 13 31 
145 (119) Multifactorial - -  -23.3 +11.8 -19.2 05§ -0.024§ 3 2 6 19 
Risk reduction 16.4 
MAAS (41) 4 188 (167) Placebo 0 +1 -3  +4 +3.7 -0.01 11 5 7 34 
193 (178) Simvastatin -23 -31 +8 -18 +0.6 -0.07 8 4 11 23 
REGRESS (44) 2 434(330) Placebo +1 +2 0 -5  +3.5 -0.09 7 5 13 69 
450 (324) Pravastatin -18 -25 +9 -17 +2.5 -0.03 5 3 8 44 
*Numbers in parentheses are number of patients (Pts) completing final angiography. ?Absolute number of patients with an event. ~Total cardiac events. §Rate of 
change per year in visibly diseased vessels. CABG - coronary bypass graft surgery; CCAIT - Canadian Coronary Atherosclerosis Intervention Trial; FATS - Familial 
Atherosclerosis Study; HARP = Harvard Atherosclerosis Reversibility Project; Lifestyle = Lifestyle Heart Trial; MAAS = Multicentre Anti-Atheroma Study; 
MARS = Monitored Atherosclerosis Regression Study; PTCA = percutaneous transluminal coronary angioplasty; SCOR = Specialized Center of Research; SCRIP = 
Stanford Coronary Risk Intervention Project; STARS - SL Thomas' Atherosclerosis Regression Study; other abbreviations a in Tables 1 and 2. 
994 FORRESTER ET AL. JACC Vol. 27, No. 5 
TASK FORCE 4 April 1996:964-1047 
high density lipoprotein (HDL) were important contributors to
the beneficial effects. Reductions in LDL cholesterol correlate 
better with reduced rates of progression, and increased HDL 
cholesterol levels correlate better with increased rates of 
regression. 
There are still a number of inconsistencies in the angio- 
graphic trials. Some trials, for instance, showed a major effect 
on decreasing the rate of progression for lesions with >50% 
diameter stenosis, whereas others showed that the predomi- 
nant effect is on new lesions and those <50%. Some showed a 
therapeutic effect primarily in patients with small, dense LDL 
particles; still other trials found effectiveness primarily with 
resins and niacin therapy. 
The most recent studies involve the HMG-CoA reductase 
inhibitors. A reduction in clinical events was demonstrated 
both in large clinical trials and in smaller studies uch as the 
Pravastatin Multinational Study (46). The most conclusive trial 
to evaluate clinical events is the Scandinavian Simvastatin 
Survival Study (4S) (47). The mean changes in total cholesterol 
(-25%), LDL cholesterol (-35%) and HDL cholesterol 
(+8%) were statistically significant. These changes in blood 
lipids were associated with a 30% to 35% reduction in both 
mortality and major coronary events. Similar reductions in 
clinical events were noted in a subgroup analysis that included 
patients with LDL cholesterol levels in the upper and lower 
quartiles at baseline, women and patients ->60 years old. The 
study also demonstrated that long-term (5-year) administra- 
tion of a HMG-CoA reductase-inhibiting drug was safe and 
that here was no increase in non-coronary heart disease death. 
A similar 30% reduction in all cardiovascular events was 
reported in a recta-analysis involving 1,891 subjects who were 
followed for approximately 4 years with random assignment to 
either placebo r pravastatin (48). Although the numbers were 
small, a 60% reduction was observed when nonfatal myocar- 
dial infarction was combined with fatal myocardial infarction, 
coronary heart disease death and total mortality. 
For asymptomatic patients, the most definitive study is the 
West of Scotland study (49). In this study, 6,595 men without 
a history of myocardial infarction, with a mean plasma choles- 
terol of 272 mg/dl, were randomized to receive pravastatin 
(40 nag each evening) or placebo. The average follow-up eriod 
was 4.9 years. Pravastatin lowered the mean plasma LDL 
cholesterol evel by 25%. The relative risk of a definite 
coronary event (nonfatal myocardial infarction or death from 
coronary heart disease) was reduced by 31%. The reduction i  
risk first became apparent at 6 months after initiation of 
treatment and continued to increase throughout the 5 years of 
the trial. The relative reduction i  risk was not affected by age 
or smoking status. There were no excess deaths from noncar- 
diovascular causes in the pravastatin group. 
Taken together, the clinical trial data allow us to conclude 
that elevated serum lipid levels contribute directly to the 
development of atherosclerosis, and that lowering blood lipids 
reduces clinical events and mortality in patients with and 
without known coronary heart disease. 
Clinical lessons from cholesterol lowering trials. The clin- 
ical trial data suggest hat in patients with coronary artery 
disease, treatment of lipid abnormalities should not be con- 
fined to those with striking abnormalities. For instance, in the 
Familial Atherosclerosis Treatment Study (FATS) trial both 
reduction in clinical events and beneficial arteriographic 
change appeared to be most evident in patients with baseline 
LDL cholesterol <160 mg/dl (50). In the Stanford Coronary 
Risk Intervention Project (SCRIP) and Cholesterol Lowering 
Atherosclerosis Study (CLAS) investigations, patients were 
not selected on the basis of hypercholesterolemia, and yet 
arteriographic benefit was seen in response to lipid and 
life-style therapy. 
Furthermore, the 4S trial demonstrated similar outcomes 
associated with LDL cholesterol reduction in the subgroups 
with initially high and low entry LDL cholesterol levels (51). 
These data establish the need to provide aggressive lipoprotein 
treatment to all patients with coronary artery disease, even if 
LDL cholesterol iswithin a range currently considered to be 
acceptable for patients without. The National Cholesterol 
Education Program recommends an LDL cholesterol level of 
100 mg/dl or less as a good target. 
There may be a gender difference in response to therapy. In 
some studies, arteriographic change in men and women receiv- 
ing similar treatment has demonstrated statistically significant 
improvement in women, but not men (37). This suggests that 
women derive at least equal, and perhaps greater, benefit from 
lipid-lowering therapy. 
In patients with coronary artery disease who exhibit signif- 
icant LDL cholesterol reduction, elevated triglyceride-rieh 
lipoproteins and low HDL predict outcome. It seems possible 
that triglyceride- and cholesterol-rich lipoproteins have a dif- 
ferential effect on mild/moderate and severe lesion progression 
as assessed by quantitative coronary angiography (52). 
Finally, despite LDL cholesterol reduction, arteriographic 
progression continues in many patients. Coronary arterio- 
graphic trials demonstrate continued lesion progression in 
25% to 60% of subjects even with the most aggressive LDL 
cholesterol lowering. Maximum benefit may require manage- 
ment of other lipid abnormalities and risk factors. 
Hypertension 
There is a large body of data relating both diastolic pressure 
and systolic pressure to coronary heart disease. In a meta- 
analysis of nine prospective trials, MacMahon et al. (53) found 
a close relationship between diastolic blood pressure and the 
incidence of stroke and coronary heart disease. Among 
420,000 people followed for 6 to 25 years, there were 599 fatal 
cerebrovascular events, and 4,260 deaths from coronary heart 
disease. Arterial diastolic pressures of 105 mm Hg or greater 
were associated with a fourfold increase in risk of coronary 
disease relative to the lowest quartile of risk. Further, these 
pooled data demonstrated a direct continuous independent 
association of blood pressure and risk, with no evidence of any 
"threshold" risk level of blood pressure. 
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Table 4. Results of Antihypertensive Th rapy in 17 Randomized, 
Placebo-Controlled Trials (47,653 patients)* 
Reduction 
Drug Placebo (mean - SD) 
Total strokes 2.2% 3.5% 38 -+ 4% 
Fatal 0.6% 1.0% 40 + 8% 
Nonfatal 1.6% 2.5% 37 -- 5% 
Total coronary disease 3.9% 4.6% 16 _+ 4% 
Fatal 2.0% 2.4% 16 _+ 5% 
Nonfatal 1.9% 2.3% 15 _+ 6% 
*Modified, with permission, from Collins et al. (59). 
The importance of systolic blood pressure as a risk factor 
was emphasized in MRFIT, which demonstrated that the risk 
of coronary disease, stroke and mortality was more correlated 
with systolic than with diastolic pressure (54). The level of risk 
associated with elevated blood pressure varies substantially 
with gender, race and age. Studies of women have shown that 
they have lower morbidity and mortality rates at any level of 
hypertension (55). The MRFIT also included 23,000 black men 
followed for 10 years. The mortality rate from coronary heart 
disease for men with diastolic blood pressure above 90 mm Hg 
was lower in black men than in white men, with a relative risk 
of 0.84, whereas the mortality rate for cerebral vascular disease 
was higher for black men, with a relative risk of 2.0 (56). 
Perhaps the most important risk factor is age. Beyond the 
risk associated with the progressive rise in blood pressure with 
age, elderly people have a greater risk of cardiovascular events 
at every level of pressure. For instance, the risk of a diastolic 
blood pressure of 95 mm Hg is threefold to fourfold greater for 
patients 65 to 94 years old than patients with the same arterial 
pressure 35 to 64 years old (4). 
Finally, the risk of hypertension cannot be taken in isola- 
tion. The risk of hypertension is unevenly distributed and 
closely related to the magnitude and number of coexisting risk 
factors, including hyperlipidemia, diabetes and smoking (57). 
Based on the demonstrated continuum of blood pressure and 
risk, the blood pressure problem involves most of the popula- 
tion, not only the substantial minority with clinical hyperten- 
sion. 
The Veterans Affairs Cooperative Study was the first to 
definitively demonstrate he value of treatment of hyperten- 
sion (58). By 1993 there were 17 randomized trials of therapy 
in over 47,000 patients of both genders, all races and a wide 
spectrum of pressures (59) (Table 4). The difference between 
the treated group and the control group was 13 mm Hg in 
systolic pressure and 6 mm Hg in diastolic pressure. This 
degree of blood pressure reduction produced approximately 
38% fewer strokes, but only 16% reduction i  the incidence of 
coronary heart disease. 
Recent interest in the influence of age on the efficacy of 
antihypertensive therapy has led to subset analysis of older 
(>60 years) and younger subjects in prior trials and to several 
newer trials in the elderly. Reanalysis has demonstrated that 
older and younger individuals experience similar percent re- 
duction in events, but a greater absolute reduction of events in 
the elderly. The absolute reduction of coronary events in the 
older subjects (2.7/1,000 person-years) was more than twice as 
great as that in the younger subjects (1.0/1,000 person-years) 
(6O). 
Demographics and severity of hypertension did not signif- 
icantly impact on the percent reduction in morbid events from 
antihypertensive therapy. Thus, women and men exhibited a 
reduction in events similar to black and white subjects. The 
observation that absolute blood pressure level did not signifi- 
cantly alter the percent reduction of events has led to the 
suggestion that antihypertensive drugs may even be effective in 
reducing cardiovascular events in normotensive subjects at risk 
for morbid events (60). 
Most of the published controlled trials in hypertension have 
utilized diuretics or beta-blockers, orboth. Because the newer 
classes of drugs (calcium antagonists, angiotensin-converting 
enzyme inhibitors) have not yet been subjected to such large- 
scale trials, a possible drug-dependent difference in magnitude 
of effect cannot be excluded. Nonetheless, the data clearly 
demonstrate a lesser benefit of antihypertensive therapy on 
coronary than on cerebrovascular events. Although the mech- 
anism of this surprisingly modest benefit on coronary events is 
not fully understood, several possibilities have been enter- 
tained. Too great a reduction in diastolic blood pressure has 
been suggested as a possible cause of adverse coronary events 
in patients with coronary disease (the J-shaped curve) (61). 
Alternative xplanations are that coronary disease may be 
more multifactorial than cerebrovascular disease; that the 
short duration of the trials may limit the benefit of the 
treatment on this slowly progressive coronary disease; that 
some treatment regimens may adversely affect other coronary 
risk factors, such as hyperlipidemia and insulin resistance; and 
that clinical documentation f coronary events may be impre- 
cise. 
The efficacy of nonpharmacologic interventions in reducing 
coronary events in hypertensive patients has not been well 
documented. Weight reduction and salt restriction are effective 
means for reducing the blood pressure if they can be accom- 
plished. Weight reduction also helps control insulin resistance. 
Salt restriction, however, may be associated with an increase in 
plasma renin activity, which may be a risk factor for vascular 
events (62). Potassium supplementation also may be vascular 
protective. Regular exercise has been associated with a reduc- 
tion in rest blood pressure and heart rate. If these life-style and 
dietary alterations can reduce blood pressure, then pharmaco- 
logic intervention may be unnecessary. However, such a strat- 
egy should be based on equally compared antihypertensive 
pharmacologic and nonpharmacologic therapies. Such data 
have not yet been collected. 
Strategies to enhance clinical elficaey of antihypertensive 
therapy. The modest efficacy of antihypertensive therapy on 
coronary events in clinical trials may underestimate th  efficacy 
of this therapy in selected populations. In general, the higher 
the risk in the population, the greater the magnitude of 
response to therapy. Identifying a high risk population may 
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Table 5. Responses toTherapy in Hypertensive Subjects 
Morbid Blood 
Events Pressure LVH LDL/HDL 
Weight loss ? $ ? 
Salt restriction ? $ ? 
Exercise ? $ ? I' ,~ 
Diuretic drugs $ $ $ 
Beta-blocker ~, ~ ~ I' 
ACE inhibitors ? ~ $ 
Calcium antagonists ? J, $ 
Alpha-blockers '~ ~, ? ,~ 
ACE = angiotensin-converting e zyme; LVH = left ventricular hypertro- 
phy; $ = decrease; 1" = increase; ~ = no change; other abbreviations a  in 
Table 2. 
include consideration of age, elevated nocturnal blood pres- 
sure, elevated ambulatory blood pressure, left ventricular 
hypertrophy, proteinuria, evidence of vascular disease by im- 
aging techniques and reduced vascular compliance stimated 
by emerging techniques. 
Drug therapy aimed at reducing blood pressure is the most 
commonly employed approach. The JNC-V recommendations 
include five different classes of drugs that may be effective as 
monotherapy. The relative benefits of each of these interven- 
tions as a means of preventing coronary events has not been 
well established. This is currently the subject of a new long- 
term trial, the Antihypertensive and Lipid-Lowering Trial to 
Prevent Heart Attack (ALLHAT). Blood pressure treatment 
guidelines often fail to identify the frequency of measurements 
that should be utilized for risk assessment. Single blood 
pressure measurements are notoriously unreliable and Vari- 
able. Frequent blood pressure measurements in the clinic or at 
home provide a better picture. Another strategy is to do 
ambulatory monitoring for 24 h, during which the blood 
pressure can be tracked at frequent intervals during wakeful- 
ness and during sleep. It is important o assess the average 
blood pressure reading rather than single isolated readings. 
Although blood pressure is usually chosen as the therapeu- 
tic goal for pharmacologic therapy, more attention is currently 
being directed toward the other physiologic end points associ- 
ated with risk described previously (Table 5). Therefore, 
optimal treatment of the hypertensive patient to prevent 
coronary events may include therapy that inhibits vascular wall 
thickening, normalizes arterial compliance, prevents or re- 
verses left ventricular hypertrophy, corrects proteinuria, nor- 
malizes endothelial dysfunction and reverses insulin resistance. 
The efficacy of various therapeutic regimens on these end 
points needs to be established before recommendations can be 
provided as to optimal therapy. Furthermore, since the re- 
sponse of hypertensive subjects to different antihypertensive 
drugs varies widely, it is unlikely that any single category of 
drugs will be equally effective on all end points or in all 
subjects. Therefore, it is urgently necessary--if these end 
points are important in determining a favorable long-term 
preventive strategy--that we develop simple surrogates that 
allow the physician to determine whether an actual treatment 
strategy ishaving a favorable ffect. Blood pressure alone may 
not be an adequate surrogate for the favorable effect on 
vascular injury or the atherosclerotic process. 
Smoking 
The magnitude of risk associated with cigarette smoking is 
similar to that associated with hypertension and hypercholes- 
terolemia; however, because cigarette smoking is present in a 
greater proportion of our population, it ranks as the largest 
preventable cause of coronary artery disease. 
Epidemiologic observational studies consistently show that 
former smokers have coronary disease vents at a significantly 
lower rate than current smokers (62). One observational study 
of 564 post-myocardial infarction patients demonstrated that 
recurrent disease risk is reduced by 50% within 1 year of smok- 
ing cessation and normalizes to that of nonsmokers within 
2 years (63). 
Three randomized smoking cessation trials have been per- 
formed (64-66). None of these trials included patients with 
coronary artery disease. The reduction in cardiac event rate in 
these trials ranged from 7% to 47%. The rapidity of risk 
reduction after smoking cessation is consistent with recent 
research that demonstrates that smoking causes transient and 
reversible prothrombotic increase in fibrinogen levels (67) and 
platelet adhesion (68). Other rapidly reversible effects of 
smoking include increased blood carboxyhemoglobin levels, 
reduced HDL cholesterol (69) and coronary artery vasocon- 
striction (70). 
Clinical strategies for smoking cessation. There is en- 
hanced receptivity to smoking cessation after a cardiac event, 
which provides awindow of opportunity for secondary preven- 
tion. Although up to 32% of patients will stop smoking at the 
time of a cardiac event, this rate can be significantly enhanced 
to 61% by a nurse-managed smoking cessation program, as 
demonstrated byTaylor and co-workers (71). New behavioral 
and pharmacologic approaches tosmoking cessation are avail- 
able and can be administered by trained allied health care 
professionals (71). The importance of a structured approach 
cannot be overemphasized. The rapidity and potency of risk 
reduction, as well as the other health-enhancing effects asso- 
ciated with smoking cessation, argue for the prioritization of 
smoking cessation in any program of secondary prevention of 
coronary disease. 
Antithrombotic Therapy 
Although there are multiple trials examining the use of 
aspirin for the secondary prevention i  coronary artery disease, 
no single study has provided efinitive results. A meta-analysis 
of 18,000 patients revealed that platelet inhibitor therapy 
reduced cardiovascular mortality by 13%, nonfatal reinfarction 
by 31% and nonfatal stroke by 42% (72). Aspirin alone was as 
effective as the combination of aspirin and dipyridamole and 
more effective than sulfinpyrazone. Medium dose aspirin (75 to 
325 rag) was as efficacious as higher dose aspirin. 
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A 5-year trial of aspirin plus dipyridamole in patients with 
stable angina found reduced angiographic lesion formation, no 
effect on lesion progression and a 67% reduction in the 
incidence of myocardial infarction (12% to 4%) (73). Another 
study of 333 men with chronic stable angina found that aspirin 
alone reduced the incidence of myocardial infarction by 87% 
but with only a slight decrease in mortality (74). The risk of 
stroke increased. Similar effects of aspirin in patients with 
stable coronary disease have been reported in other studies 
(75). 
There are also many studies of anticoagulants in secondary 
prevention. In the Anticoagulants in the Secondary Prevention 
of Events in Coronary Thrombosis (ASPECT) trial, patients 
were randomized to phenprocoumon or acenocoumarin or 
placebo (76). The anticoagulant therapy was titrated to achieve 
an international normalized ratio (INR) of 2.8 to 4.8. Although 
there were no significant differences in mortality, there was a 
significant (53%) reduction in recurrent myocardial infarction 
in the anticoagulant-treated groups. In the Warfarin and 
Reinfarction Study (WARIS), patients were randomized after 
initial acute myocardial infarction to warfarin (target INR 2.8 
to 4.8) or placebo (77). Patients were advised not to take 
aspirin during the trial. At mean 3-year follow-up, warfarin 
resulted in a significant reduction of mortality, total reinfarc- 
tions, nonfatal infarctions and total strokes. 
In the Sixty Plus Reinfarction Study, patients over 60 years 
of age were randomly assigned to anticoagulant therapy or 
placebo for 2 years (78). Patients receiving anticoagulant 
therapy had a 26% lower death rate and a 51% lower rate of 
reinfarction (8.4% vs. 4.1%) than patients taking placebo. A 
trend toward reduced frequency of cerebrovascular events also 
was observed. 
The German-Austrian Myocardial Infarction Study (GAMIS) 
compared warfarin therapy with antiplatelet herapy (79). 
Patients were randomized after-acute myocardial infarction to 
open-label phenprocoumon (target INR 2.5 to 5.0), aspirin 1.5 
g/day or placebo. There was no difference between groups in 
mortality or infarction. Similarly, the French Enquete de 
Prevention Secondaire de l'Infarctus de Myocarde (EPSIM) 
found no difference in death or infarction after oral anticoagu- 
lants or aspirin, but there were 54% more gastrointestinal 
events with aspirin, and four times more severe hemorrhagic 
events with warfarin (80). In the Aspirin Versus Coumadin in 
the Prevention of Reocclusion and Recurrent Ischemia After 
Successful Thrombolysis (APRICOT) trial, patients were ran- 
domized to either 325 mg of aspirin/day or to heparin followed 
by warfarin (target INR 2.8 to 4.0) after an initial angiogram 
<48 h after acute myocardial infarction revealed a patent 
infarct-related artery (81). At 3 months, there was no signifi- 
cant difference in either mortality or coronary reocclusion 
rates among the three groups. Aspirin significantly reduced 
reinfarction compared with placebo but not warfarin (mortality 
rates of 3%, 11% and 8%, respectively). From these data, we 
may conclude that the most efficacious anticoagulant/ 
antiplatelet therapy in secondary prevention of coronary cases 
has yet to be defined. 
There are two ongoing studies examining the unresolved 
issue concerning combined use of anticoagulants and anti- 
platelet agents after acute myocardial infarction (82). The 
Coumadin Aspirin Reinfarction Study (CARS) trial is studying 
patients randomized to three treatment regimens: 1) 160 mg/day 
of aspirin; 2) 80 mg/day of aspirin plus 3 nag/day of warfarin; 
3) combination pill of 80 mg of aspirin plus 1 mg of warfarin/ 
day. The Combination Hemotherapy and Mortality Prevention 
(CHAMP) study is randomizing patients to receive either 
160 mg/day of aspirin or 80 mg/day of aspirin plus warfarin 
sodium (Coumadin) to achieve an INR of 1.5 to 2.5. 
The value of aspirin in primary prevention also has been 
tested in two randomized trials, the U.S. Physicians' Health 
Study (83) and the British Doctors' Trial (84). The American 
trial included 22,000 male physicians, 40 to 84 years old, 
assigned to receive aspirin (325 mg every other day) or placebo 
for 5 years. There was a 44% reduction in the incidence of 
myocardial infarction (from 0.4% to 0.2% per year), limited to 
those older than 50 years. Over the 5-year period, the inci- 
dence of cardiovascular death was similar in the aspirin and 
placebo groups. In the aspirin-treated group, there was a 
statistically insignificant increase in hemorrhagic stroke (0.2% 
vs. 0.1%) but a significant increase in gastrointestinal hemor- 
rhage requiring transfusion (0.5% vs. 0.3%). In the British trial 
of 5,000 male physicians, 50 to 78 years old, two-thirds were 
randomly assigned to take aspirin (500 mg/day) and one-third 
were instructed to avoid it (no placebo used). At 6 years, there 
was no difference in myocardial infarction or cardiovascular 
death, with a slight increase in disabling strokes in the aspirin 
group. Because the prevalence of cardiovascular events was 
quite low among the participants in these trials, the absolute 
risk reduction was quite small. For myocardial infarction in the 
American study, it was less than two events per 1,000 patients 
per year. Therefore, we may conclude that the use of aspirin 
for primary prevention of coronary events in a healthy popu- 
lation is open to question. 
Clinical lessons from antithrombotic trials. In low risk, 
apparently healthy populations, the rate of myocardial infarc- 
tion was consistently higher among patients with coronary risk 
factors than among those without, ranging from 1.4-fold in 
those with a parental history of coronary disease to 5-fold in 
those with diabetes, with intermediate increments associated 
with smoking, hypercholesterolemia and hypertension. Thus, 
in primary prevention, aspirin should be considered in men 
who are over the age of 50 and have risk factors for the 
development of coronary events (85). Aspirin should be used 
cautiously, if at all, in patients with poorly controlled hyper- 
tension. In this context, aspirin therapy should be viewed as a 
possible adjunct, rather than as an alternative to the manage- 
ment of coronary risk factors. Finally, although the short-term 
benefit of aspirin in these populations appears to outweigh its 
risk, the long-term advantages and toxicity of the drug remain 
uncertain. 
Although observational epidemiologic studies in primary 
prevention have suggested a possible benefit of aspirin in 
women (86), definitive recommendations await the results of 
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the Women's Health Study, a large randomized trial of low 
dose aspirin use among more than 40,000 female nurses who 
are 45 years old and older. In an ongoing thrombosis preven- 
tion trial among men at high risk of coronary heart disease, the 
effects of low dose aspirin (75 rag/day), low dose warfarin and 
the combination of both agents are being evaluated. The 
results of this trial will further define the role of antithrombotic 
agents in primary prevention. 
The trials of aspirin and anticoagulants for secondary 
prevention in both survivors of myocardial infarction and 
patients with stable coronary disease indicate that these agents 
convey protection against death and reinfarction. The advan- 
tage of aspirin over anticoagulant agents is not higher effec- 
tiveness but rather lower cost, ease of administration a d less 
need for monitoring. For coronary patients, therefore, aspirin 
is the preferred therapy. Anticoagulants are favored for indi- 
viduals with aspirin intolerance, those at risk of embolism from 
the left ventricle (i.e., mural thrombi and severe myocardial 
dysfunction) or the left atrium (i.e., atrial fibrillation) or with 
prior embolism. 
Multifactorial Risk Modification 
In clinical practice, risk factors appear in combinations, and 
treatment is multifactorial. There are few clinical trials that 
deal with multiple risk factor interventions. Meta-analyses of 
randomized, controlled trials of cardiac rehabilitation have 
demonstrated a 26% lower total mortality rate in those pa- 
tients who combined multifactorial risk factor counseling with 
exercise than patients who utilized predominantly exercise 
alone (87). Two large multifactorial risk modification trials 
have also demonstrated a cardiac mortality rate reduction of 
24% to 26% (88,89), suggesting that multifactorial risk modi- 
fication is beneficial. Recently, the SCRIP trial demonstrated 
that multifactorial risk modification achieves a 50% reduction 
in cardiac events associated with improvement i  the manage- 
ment of serum lipids, hypertension, diabetes, smoking cessa- 
tion and exercise (42). From these data, we may conclude that 
multifactorial risk factor reduction will reduce cardiac events 
in patients with coronary disease. 
II. Factors for Which Interventions 
Are Likely to Lower Coronary 
Artery Disease Risk 
Diabetes 
There have been no clinical trials designed specifically to 
test whether glucose control in diabetic patients will prevent 
macrovascular ( therosclerotic) complications ofdiabetes. How- 
ever results of a recent large trial (90) indicate that improved 
glucose control reduces the microvascular complications of 
insulin-dependent diabetes mellitus. Whether improved glu- 
cose control will prevent macrovascular complications in pa- 
tients with non-insulin-dependent diabetes mellitus (NIDDM) 
remains to be tested. Limited data indicate that control of 
other isk factors in patients with NIDDM will reduce coronary 
events. Further, on the basis of the known adverse ffects of 
prolonged hyperglycemia, t is likely that benefit for coronary 
heart disease risk reduction will result from improved glucose 
control; but convincing clinical trials are lacking. 
Physical Inactivity/Exercise 
Low levels of physical fitness are associated with an in- 
creased risk of coronary artery disease, with relative risks up to 
eight times greater than those for physically fit persons (91). 
One observational study has shown that exercise-induced 
physical fitness in healthy and diseased subjects is associated 
with a 44% mortality reduction (92). Exercise also beneficially 
alters coronary disease risk factors, such as HDL cholesterol. A 
recent quantitative angiographic trial in patients with coronary 
disease demonstrated atherosclerotic disease regression simi- 
lar to that observed in the lipid trials associated with intense 
aerobic exercise (93). The most beneficial angiographic change 
was evident in the group expending 2,000 kcal/week of physical 
activity, roughly equivalent to 1 h of daily aerobic exercise. 
There are 22 exercise trials performed predominantly in 
myocardial infarction survivors. Because assessment ofcardiac 
events requires a large sample size, none of these trials has 
included sutficient numbers of patients. For this reason, the 
results are frequently pooled. A compilation of these 22 trials 
(94) and a meta-analysis of 10 trials (87) both concluded that 
exercise reduces total mortality and cardiac mortality by 20% 
to 25% in patients with coronary disease (Table 6). Although 
there was no reduction in nonfatal myocardial infarction, 
subgroup analysis demonstrated a 37% reduction in sudden 
cardiac death (94). Recent observational data further suggest 
that the reduction in total mortality may be even greater than 
the improvement in coronary disease vent rate (91,104). 
Clinical lessons from the therapeutic application of exer- 
cise. Exercise is an important cornerstone to the secondary 
prevention of coronary disease, particularly for the prevention 
of sudden cardiac death, and yet data suggest hat very few 
patients with coronary disease will initiate and sustain an 
exercise program without some type of supervision and struc- 
ture (105). By contrast, structured exercise programs involving 
frequent staff contact and program review with the patient 
significantly enhance compliance to exercise (106). Exercise 
may also enhance compliance to other life-style changes uch 
as smoking cessation (107). The combined use of preventive 
measures can be cost effective (108). 
Whether structured exercise should be electrocardiograph- 
ically monitored isan area of current controversy. Supervised, 
on-site exercise with continuous telemetry ECG monitoring 
represents he most expensive component of current cardiac 
rehabilitation programs. This type of staff supervision and 
monitoring during exercise has been found to result in a high 
frequency of medical problem identification and patient care 
alteration (109,110). Electrocardiographic monitoring should 
not be considered an all-or-none phenomena, however. It is 
possible, based on assessment ofrisk of a cardiac event during 
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Table 6. Rehabilitation Exercise Trials 
Study No. of Fatal and Nonfatal CHD 
(ref. no.) Year Duration Intervention Pts [no. (%) of pts] 
Kentala (95) 1972 1 yr 
Wilhelmson et al. (96) 1975 4 yr 
Kallio et al. (89) 1979 3-12 mo 
Shaw (97) 1981 3 yr 
Carson et al. (98) 1982 3 mo 
Rechnitzer et al. (99) 1983 4 yr 
Roman et al. (100) 1983 3.5 yr 
Vermuelen et al. (101) 1983 6-8 wk 
WHO (102) 1984 6 wk-3 yr 
Marra et al. (103) 1985 8-9wk 
Exercise 77 14 (18) 
Control 81 14 (17) 
Exercise 158 53 (33) 
Control 157 61 (48) 
Exercise/risk factor 188 49 (26) 
modification 
Control 187 76 (14)* 
Exercise 323 29 (9) 
Control 328 31 (9) 
Exercise 151 11 (8) 
Control 152 10 (7) 
Exercise 379 54 (14) 
Control 354 46 (13) 
Exercise 93 22 (24) 
Control 100 32 (32) 
Exercise 47 6 (13) 
Control 51 14 (27) 
Exercise/risk factor 705 159 (23) 
modification 
Control 655 146 (23) 
Exercise 81 10 (12) 
Control 80 13 (16) 
*p < 0.05, treatment group versus control group. Abbreviations as in Table 1. 
exercise, to assign a high risk group to continuous ECG 
monitoring, an intermediate risk group to intermittent moni- 
toring and the remaining low risk group to supervised exercise 
with minimal to no monitoring (110,111). High risk patients, 
who typically represent about 20% to 25% of cardiac rehabil- 
itation populations, may benefit he most from a high level of 
supervision and monitoring (112). Alternative measures could 
also be undertaken to most effectively use ECG monitoring. 
Miller et al. (113) have shown that structured home exercise 
programs for low risk patients with coronary disease that 
utilize intermittent transtelephonic ECG monitoring are a safe 
and efficacious alternative for increasing functional capacity. 
Thus, secondary preventive programs hould increasingly be 
structured to offer a variety of exercise programs, with and 
without ECG monitoring, tailored to patient needs and logis- 
tical considerations. These can range from formal on-site 
groups to structured home exercise to some combination of 
approaches. 
High Density Lipoprotein Cholesterol 
Increasing HDL cholesterol levels is a lesser priority for 
lipid-lowering therapy than LDL cholesterol reduction (114). 
Beyond life-style change, niacin and estrogen, the therapeutic 
options for HDL cholesterol elevation are limited. The incre- 
mental benefit and cost-effectiveness of increasing HDL cho- 
lesterol evels in patients who have LDL cholesterol levels of 
<100 mg/dl has not been established. 
Because many lipid-active agents and life-style changes 
affect multiple lipids simultaneously, it has been difficult to 
demonstrate hat increasing HDL cholesterol independently 
lowers coronary heart disease risk. No completed trial has been 
able to address the efficacy of raising HDL cholesterol alone; 
several are under way. Although there is no consensus, ome 
have attributed the marked beneficial effect of gemfibrozil n 
the Helsinki Heart Study to increases in HDL (29). It is 
possible that less aggressive therapy for LDL cholesterol levels 
might be possible if HDL cholesterol levels could be increased 
significantly (114). The relative importance of the desired total 
cholesterol/HDL or LDLMDL ratios, therefore, requires fur- 
ther data collection and analysis. 
Triglycerides and Small, Dense Low 
Density Lipoprotein 
Elevated triglycerides are associated with multiple meta- 
bolic abnormalities, including low HDL; small, dense LDL 
insulin resistance; abdominal obesity; and an increased risk for 
coronary artery disease. Although no clinical study has conclu- 
sively demonstrated a reduction in coronary artery disease risk 
associated with triglyceride lowering, the angiographic data 
suggest a relationship. Retrospective analyses of five angio- 
graphic trials suggest that LDL cholesterol levels may not be 
the best predictors of progression and regression (40,52, 
115-119). Baseline triglyceride levels (which correlate with 
LDL density and subclass); intermediate density lipoprotein 
(IDL); other triglyceride-rich particles (especially those con- 
taining apolipoprotein [apo] C-III); and small, dense LDL 
(also termed subclass B) were better predictors of a beneficial 
angiographic outcome. Despite similar LDL cholesterol reduc- 
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tions, the benefits of treatment were frequently limited to 
patients with high triglycerides, increased IDL and small, 
dense LDL. Additional prospective studies are required to 
assess the significance of these observations, especially the 
correlation with clinical events and the response to individual 
drug therapies. 
Obesity 
No study has specifically examined the effect of weight loss 
on coronary heart events. However, the role of weight reduc- 
tion in the treatment of hypertension, dyslipidemia and diabe- 
tes makes it an obvious choice for an intervention. 
Hormone Replacement Therapy 
Because of the marked difference in the prevalence of 
coronary disease between men and premenopausal women of 
the same age, estrogens have long been thought o protect 
against coronary artery disease. Studies in the 1950s uggested 
that estrogen was a potent lipid-altering agent hat protected 
against development of atherosclerosis n animal models 
(120,121). In the 1960s and 1970s, however, clinical trials of 
estrogen in men and observational studies of oral contracep- 
tives in women demonstrated an unexpected and consistent 
increase in the risk of cardiovascular disease. As recently as 10 
years ago, an American Heart Association (AHA) pamphlet 
on prevention of coronary artery disease in women reported 
that estrogen use increased coronary artery disease. In the 
1980s and 1990s, however, the marked reduction in coronary 
events observed in postmenopausal women receiving estrogen 
led to a reevaluation of the relationship between estrogen and 
cardiovascular disease. 
It has been hypothesized that estrogen-induced changes in 
lipids are the primary mechanisms of cardioprotection. Re- 
cently, other actions, including estrogen-induced changes in 
serologic risk factors {e.g., fibrinogen, lipoprotein [Lp(a)]}, 
direct actions of estrogen on the vessel walls, estrogen- 
associated calcium antagonist effects, estrogen-associated an- 
tioxidant effects and estrogen-induced genetic changes have 
been discovered, all of which could protect against atheroscle- 
rosis (122-127). 
A large body of evidence suggests that hormone use in 
postmenopausal women may provide primary protection 
against the development of coronary artery disease. Almost 
every observational cohort study that has focused on this issue 
has found that women who use estrogens have a substantially 
lower risk of developing coronary artery disease than women 
who do not. Several meta-analyses, encompassing more than 
30 studies, suggest hat the initial clinical presentation of 
coronary artery disease may be reduced by 30% to 70% in 
women using postmenopausal hormones (128-130). Data 
from the Lipid Research Clinics Follow-up Study found that 
after 9 years, estrogen users had a 64% lower risk of coronary 
artery disease mortality than nonusers (131). Statistical adjust- 
ment for known coronary artery disease risk factors, including 
blood pressure, smoking and lipids, did not alter the estimate. 
Additional statistical analysis uggested that about 50% of the 
protection was effected through estrogen-induced increases in 
HDL cholesterol. 
Reductions in coronary artery disease risk also have been 
reported in angiographic, autopsy and case-control studies and 
a small clinical trial (122,132). In four published angiographic 
reports, the amount of coronary atherosclerosis was signifi- 
cantly less (40% to 70%) in hormone users than nonusers, 
irrespective of other coronary artery disease risk factors. Five 
observational studies have assessed the impact of estrogen 
therapy on women with coronary artery disease. All show 
reductions in risk of subsequent death ranging from 70% to 
90%. For example, data from the Lipid Research Clinics 
Follow-up Study demonstrated that in patients with a previous 
myocardial infarction or stroke, hormone users had nearly a 
90% reduction in subsequent coronary artery disease death 
compared with nonusers after adjustment for other coronary 
artery disease risk factors. In a 10-year follow-up study of 
women who had angiographically severe coronary stenosis, 
Sullivan et al. (133) found a marked reduction in coronary 
artery disease deaths among hormone users compared with 
nonusers. 
There are a number of methodologic issues and unan- 
swered questions about hormone replacement therapy. Virtu- 
ally all studies that have assessed the effect of hormone use on 
coronary artery disease in women (either primary or secondary 
prevention) have been observational in design. Such studies 
are open to the criticism that unrecognized biases account for 
some or all of the observed protective ffects of hormone use. 
For instance, healthier women might be more likely to be 
prescribed estrogen and therefore less likely to get coronary 
artery disease, or estrogen users may exhibit higher compliance 
for all prevention therapies. Randomized clinical trials are the 
only accurate method for addressing these limitations. 
The Postmenopausal Estrogen/Progestin I tervention 
(PEN) was a large randomized clinical trial to examine the 
impact of various combinations of hormones on coronary 
artery disease risk factors (134). The trial included 875 healthy 
women 45 to 64 years old who agreed to be randomized to one 
of five potential regimens (placebo, unopposed estrogen, es- 
trogen plus medroxyprogesterone ac tate [MPA] cyclicly, es- 
trogen plus MPA continuously and estrogen plus micronized 
progesterone). The major findings of PEPI were that 1) 
unopposed estrogen and estrogen plus any progesterone im- 
proves lipoprotein levels and decreases fibrinogen levels, and 
2) unopposed estrogen and estrogen plus micronized proges- 
terone increases HDL levels to a significantly greater degree 
than either estrogen plus MPA regimen. These results upport 
the hypothesis that alteration in blood lipids is a major 
mechanism by which estrogens confer cardioprotection. In
addition, the data support anew hypothesis that estrogens may 
have a positive effect on clinically important coagulation 
factors (i.e., fibrinogen). 
The HERS study is a secondary prevention trial to test the 
efficacy of hormone therapy. This trial, unlike PEPI, has 
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Table 7. Events in Psychosocial Intervention Trials 
Study No. of Fatal and Nonfatal CHD 
(ref no.) Year Intervention Pts Duration [no. (%) of pts] 
Ibrahim et al. (140) 1974 Group psychotherapy 58 1 yr 5 (8.6) 
Control 60 15 (25.0) 
Rahe et al. (141) 1979 Group therapy 22 4 yr 0 (0) 
Control 22 5 (22.7) 
Fielding (142) 1980 Behavioral counseling and 10 3 mo 0 (9) 
relaxation training 
Control 10 1 (10.0) 
Stern et al. (143) 1983 Group counseling 35 1 yr 3 (8.6) 
Control 29 2 (6.9) 
Frasure-Smith and 1985 Nurse-managed nvironmental 232 8.3 yr 87 (37.5) 
Prince (139) stress reduction 
Control 229 110 (48.0)* 
Friedman et al. (144) 1984 Type A behavior counseling 536 4.5 yr 69 (12.9) 
and relaxation training 
Control 235 50 (21.3)* 
*p < 0.05, treatment group versus control group. Abbreviations as in Table 1. 
"hard" end points (i.e., death and recurrent myocardial infarc- 
tion). To date, over 2,500 women with documented coronary 
disease have been randomly assigned to either placebo r an 
estrogen/progestin combination. These women will be fol- 
lowed for 5 years; the results of this trial are anticipated in 
1998. 
The Women's Health Initiative (WHI) is testing the efficacy 
of hormone use for the prevention of coronary artery disease 
in a sample of women who may or may not have documented 
coronary artery disease. The WHI trial is a combination of 
several different interventions (hormones, diet, calcium sup- 
plementation) on several different end points (coronary artery 
disease, cancer, fracture). Because of the complexity of the 
study, the earliest possible date of study completion is 2002. 
Although the HERS and WHI trials may resolve many of 
the major questions about the risk and efficacy of estrogen 
therapy, there are other unanswered questions. These include 
whether nonoral routes of administration of estrogen afford 
cardioprotection to the degree seen with oral use; whether 
adding a progestin to an estrogen regimen influences cardio- 
protection; whether one dose of estrogen or progestin, or both, 
is superior to another; whether hormone use is protective 
against other vascular lesions, including ccrebrovascular dis- 
ease; and whether this hormone (or an analog) in appropriate 
doses would be helpful for cardioprotection in men. 
Clinical lessons from hormone replacement therapy trials. 
Basic genetic and laboratory research, observational studies, 
small and large epidemiologic studies and clinical trials sup- 
port an association between estrogen use and reduced risk of 
cardiovascular disease in women. Other beneficial effects of 
estrogen include fracture prevention, maintenance of muscle 
strength, amelioration of vasomotor symptoms and mainte- 
nance of vaginal functioning. Reduction in colon cancer, a 
reduction in Alzheimer's dementia, improvement in urinary 
incontinence and an improvement in memory have been 
suggested but are not yet well documented. 
The documented risks of unopposed estrogen therapy 
include an increased risk of gallbladder disease and an in- 
creased risk of endometrial hyperplasia nd carcinoma. The 
addition of progesterone to an estrogen regimen negates the 
risk of estrogen-associated carcinoma. Thus, combination hor- 
mone therapy in women with a uterus carries no additional risk 
of endometrial cancer. The issue of estrogen use and breast 
cancer remains topical and controversial (135,136). There is 
general agreement among researchers, however, that any 
increase in breast cancer isk with estrogen use is small, with 
only modest increases in risk (risk ratio of 1.1 to 1.2) (137). 
Because of methodologic issues, additional studies are unlikely 
to resolve this issue in the near future. 
III. Factors That, If Modified, 
Might Lower Coronary Artery Disease Risk 
Psychosocial Factors 
Recent observational data suggest hat the adverse prog- 
nostic impact of post-myocardial infarction depression is 
substantial (138). Data from six randomized clinical trials 
(139-144) and a recta-analysis of 11 controlled trials (145) 
demonstrate hat psychosocial stress interventions reduce re- 
current cardiac events (death and myocardial infarction) by 
35% to 75% (Table 7). Relatively small sample sizes and a 
wide divergence of stress management approaches (relaxation 
training, behavior modification and psychosocial support) have 
limited the understanding and application of these trial results. 
Nevertheless, the two trials that were adequately powered to 
assess cardiac events (139,144) and the meta-analysis (145) 
each demonstrate a similar 50% risk reduction associated with 
the psychosocial interventions. One of these large randomized 
clinical trials, performed in post-myocardial infarction pa- 
tients, demonstrated a statistically significant (51%) l-year 
reduction in cardiac death using stress management techniques 
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administered by general nurses (139). The mortality reduction 
was due primarily to a 61% reduction in non-hospital sudden 
cardiac death, an effect hat disappeared after cessation of the 
intervention, suggestive of a cause and effect. 
Clinical lessons from psychosocial intervention trials. One 
third of coronary patients qualify by DSM-III criteria as having 
disease-related depression or anxiety, or both, severe nough 
to benefit from short-term psychological treatment (146,147). 
This depression is an independent predictor of mortality in 
patients with coronary artery disease. Some studies suggest 
that the magnitude of effect is comparable to that of reduced 
left ventricular ejection fraction (147). Because psychological 
distress is treatable and impacts quality of life, identification 
and treatment of depression should be incorporated into 
secondary prevention programs. It is possible that behavioral 
treatments, such as support and stress management tech- 
niques, may also contribute to reducing recurrent cardiac 
events and mortality, as suggested by randomized clinical trials 
(139-144). Finally, after cardiac events, patients with coronary 
disease xperience an average delay in return to work of 60 
to 90 days despite low risk stratification and early hospital 
discharge. Occupational assessment and counseling has been 
found to reduce this delay in return to work by 32% (148). This 
therapy can be targeted to the subgroup of working-age 
patients within the psychosocial component of secondary pre- 
vention programs. 
Homocysteinemia 
Although elevated plasma homocysteine l vels have been 
associated with atherosclerosis r k, there are still no treatment 
data. An ongoing clinical trial at the University of Oregon will 
be completed near the turn of the century. The current 
recommended dose for folic acid and vitamins B 6 and B12 may 
not be adequate to control homocysteinemic levels. If folic acid 
is administered, it may mask the laboratory diagnosis of 
pernicious anemia and precipitate peripheral neuropathy. 
Lipoprotein(a) 
The level of Lp(a) appears to be determined principally by 
genetics. Although not yet well understood, a differential 
genetic distribution issuggested by the report hat Lp(a) levels 
are significantly higher in African-American patients (31.7 mg/dl) 
than Caucasian patients (20.4 mg/dl) (149). No study has 
specifically studied the effect of therapeutic lowering of Lp(a) 
on recurrent coronary disease vents. Medications have little 
effect on Lp(a) levels, although recent evidence suggests that 
niacin (150) and postmenopausal estrogen replacement (151) 
may have some effect. 
Oxidative Stress 
Atherogenesis appears to involve the oxidative modification 
of LDL (152,153). Prevention of such oxidation may lead to 
prevention of lesion development. However, there is no con- 
clusive clinical trial evidence that use of antioxidants reduces 
clinical cardiovascular events. There is some preliminary data 
for beta-carotene, vitamin E and probucol. In a randomized 
primary prevention trial with beta-carotene and vitamin E in 
Finnish smokers, overall mortality did not differ significantly 
between the vitamin E (50 rag/day) and control groups, 
although there were more deaths from hemorrhagic stroke in 
the vitamin E group (154). There was an insignificant decrease 
in deaths due to ischemic heart disease. Recently, a small 
subset of patients who were taking vitamin E in an anglo- 
graphic trial were reported to have less coronary artery disease 
progression and more regression (155). 
For beta-carotene, there is a preliminary report from a 
small subset of patients in the Physicians' Health Study. In 
participants who had either angina or a prior revascularization 
procedure, 50 mg of beta-carotene reduced the incidence of all 
major cardiovascular events (156). These data must be viewed 
cautiously, however, because the final report has never been 
published. 
Probucol has strong antioxidant properties, retards athero- 
sclerosis development in animals (157) and induces regression 
of tendon xanthomata in patients with familial hypercholester- 
olemia (158). The Probucol Quantitative Regression Swedish 
Trial (PQRST) (159) was a quantitative f moral artery angio- 
graphic trial in 303 patients who were followed up for 3 years. 
All patients were treated with diet and cholestyramine and 
were additionally randomized to probucol (0.5 g) or placebo 
twice daily. There was no evidence for benefit by any angio- 
graphic parameter. The potential reasons for this lack of effect 
are being explored. Probucol significantly lowers HDL, and 
this may counterbalance its antioxidant affects. 
Finally, there are several large ongoing trials using antioxi- 
dants. These trials, using both monotherapy and regimens of 
two or three antioxidants, should be completed in the next 
several years. 
Clinical lesions from oxidative stress trials. The doses at 
which the antioxidant nutrients may be effective clinically (as 
extrapolated from animal studies and supplementation stud- 
ies) are far in excess of the daily recommended intake levels. 
Randomized clinical trials using vitamin E are employing doses 
in the 400- to 1,400-IU range. It is possible that these agents 
have actions that are unrelated to their antioxidant effects. 
IV. Factors  That  Cannot  Be Modi f ied 
Family History 
The clinical importance of a family history of coronary 
artery disease can be seen in a study that demonstrated a 
genetically linked dyslipidemia in 77% of patients with coro- 
nary artery disease and 54% of their first- and second-degree 
relatives (160). 
There are four main sources of evidence linking coronary 
artery disease with genetics: 1) concentration of coronary 
artery disease in families; 2) evidence in twin studies; 3) basic 
science genetics data; and 4) phenotypes linked by inheritance 
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patterns. Family history of heart disease is one of the most 
powerful determinants of coronary artery disease risk and is 
independent of the common risk factors, including smoking, 
hypertension, diabetes, and some lipids (161,162). Numerous 
retrospective studies indicate that the risk of coronary artery 
disease in siblings of victims of premature coronary artery 
disease is approximately 50% (161). In siblings of patients with 
premature coronary artery disease studied in Finland, the risk 
of dying from coronary artery disease was 5.2 times higher than 
in a control population (163). For these reasons, first-degree 
relatives of patient s with premature coronary artery disease 
should have appropriate examination for coronary artery 
disease. 
Summary 
Observational and clinical trial data provide a substantial 
information base upon which current and future recommen- 
dations can be made for preventive therapy of coronary artery 
disease. Based on these data, it is possible to stratify potential 
therapies into four levels of anticipated effectiveness: 1) Inter- 
ventions proven to alter risk are those directed at diet, LDL 
cholesterol, hypertension, smoking and platelet adhesion. 
2) Interventions that are likely to alter risk are those directed 
at diabetes; physical inactivity; HDL cholesterol; triglycerides 
and small, dense LDL; obesity; and estrogen replacement. 
3) Interventions that might alter risk are those directed at 
homocysteine, Lp(a) and oxidative stress. 4) Risk factors that 
cannot be modified include age, gender and family history. As 
the contribution of genetically regulated risk factors are fur- 
ther defined, it seems likely that prevention of coronary artery 
disease and its complications will become progressively indi- 
vidualized and increasingly effective. 
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